RBM20 (RNA-Binding Motif Protein 20)
Details
RBM20 encodes a nuclear RNA-binding protein expressed in atrial and ventricular myocardium that regulates alternative splicing of sarcomeric genes, including TTN, MYH7 and TNNT2. Dominant variants cause a highly penetrant dilated cardiomyopathy that behaves like laminopathy — early atrial arrhythmia and rapidly progressive heart failure — which is why it is grouped with LMNA among the genotypes that warrant early identification. (sources/genetics-dcm-ccreports-2018, rating: medium)
Key Facts
- Frequency: 1–5% of familial DCM. The estimate comes from small familial cohorts and predates population-scale sequencing. (sources/genetics-dcm-ccreports-2018, rating: medium)
- Mechanism: RBM20 is a splicing regulator; loss of function alters TTN, MYH7 and TNNT2 transcripts, linking the gene to the titinopathy and sarcomeric pathways rather than to a structural protein of its own. (sources/genetics-dcm-ccreports-2018)
- Phenotype: high penetrance, pro-arrhythmic — particularly atrial fibrillation — with fast progression of heart failure. ESC 2023 describes a severe phenotype with biventricular involvement. (sources/esc-cmp-2023, rating: very high; sources/genetics-dcm-ccreports-2018)
- Gene validity: definitive for DCM in the ClinGen curation dated 2026-05-09, alongside TTN, LMNA, MYH7, SCN5A, DES, FLNC, BAG3, TNNC1 and TNNT2. (sources/clingen-summary-2026-05-09, rating: high)
- Testing: RBM20 is in the ESC 2021 minimum DCM panel, and ESC 2022 recommends testing DCM/HNDCM when AV conduction delay occurs before age 50 or when there is a family history of DCM/HNDCM or SCD before 50. (sources/HF-ESC-2021, rating: very high; sources/VA-SCD-ESC-2022, rating: very high)
- Arrhythmia-risk group: RBM20 is one of ten cardiomyopathy genes categorised as carrying heightened arrhythmia risk, alongside ABCC9, DES, DSP, FLNC, LMNA, PLN, RYR2, SCN5A and TTN, in a 4,782-patient panel cohort. (sources/genetic-yield-jama-card-2022, rating: high)
- Management: no gene-specific risk calculator exists; the rationale for early identification is the LMNA analogy — pre-symptomatic surveillance and earlier device discussion — rather than trial evidence in RBM20 carriers. (sources/genetics-dcm-ccreports-2018)
Contradictions / Open Questions
- The "behaves like LMNA" claim is an analogy, not evidence. RBM20 and LMNA share high penetrance, atrial arrhythmia and progressive heart failure, but no RBM20-specific ICD cohort, risk calculator or trial exists. Whether the LMNA 4-factor ICD threshold should transfer to RBM20 carriers is untested, and current device decisions fall back on LVEF and general DCM criteria. (sources/genetics-dcm-ccreports-2018, rating: medium; sources/esc-cmp-2023, rating: very high)
- Frequency is a 2018 estimate. The 1–5% figure comes from familial DCM cohorts and has not been replaced by a contemporary, ancestry-diverse measurement; its share of all DCM will fall as panel testing broadens. (sources/genetics-dcm-ccreports-2018)
- Biventricular versus left-dominant phenotype. ESC 2023 describes biventricular involvement, whereas the 2018 review emphasises atrial fibrillation and progressive heart failure without committing to a ventricular pattern — the imaging phenotype is not yet settled. (sources/esc-cmp-2023; sources/genetics-dcm-ccreports-2018)
- Whether early genetic identification changes outcomes is unknown. The case for pre-symptomatic intervention is extrapolated from LMNA and from the general principle that genotype-specific surveillance detects disease earlier; no RBM20 natural-history study with a screened versus unscreened comparison exists. (sources/genetics-dcm-ccreports-2018)
Connections
- Related to entities/DCM — the disease context, gene table and testing policy
- Related to entities/TTN — principal splicing target and the commonest DCM gene
- Related to entities/LMNA — the genotype it is said to resemble
- Related to concepts/Genetic-Testing-in-Cardiomyopathy — panel composition and testing indications
- Related to concepts/VA-Risk-Stratification-DCM — arrhythmic risk in non-ischaemic cardiomyopathy
- Related to concepts/Arrhythmogenic-Cardiomyopathy — overlap phenotype
- Related to concepts/Sudden-Cardiac-Death